Seroatlas · Human Serome Atlas

CLLU1

Chronic lymphocytic leukemia up-regulated protein 1

Also known as: CLLU1_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q5K131
Gene: CLLU1
Canonical length: 121 aa

OverviewNCBI Gene

No narrative summary is available for CLLU1 in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

121 residues, UniProt reviewed canonical sequence.

>Q5K131|CLLU1
     1  MFNKCSFHSS IYRPAADNSA SSLCAIICFL NLVIECDLET NSEINKLIIY LFSQNNRIRF
    61  SKLLLKILFY ISIFSYPELM CEQYVTFIKP GIHYGQVSKK HIIYSTFLSK NFKFQLLRVC
   121  W

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CLLU1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.43

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.83
gnomAD pLI: 0
gnomAD missense Z: -0.82

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Cellular components

cytoplasm

KeywordsUniProt

Cytoplasm

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CLLU1 as an antibody target. Whether an autoantibody or antibody against CLLU1 could matter depends on whether native CLLU1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CLLU1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CLLU1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...